Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma

BACKGROUND: Immune checkpoint inhibitors (ICI) induce a range of immune-related adverse events (irAEs) with various degrees of severity. While clinical experience with ICI retreatment following clinically significant irAEs is growing, the safety and efficacy are not yet well characterized. METHODS:...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Immunother Cancer
Autores principales: Abou Alaiwi, Sarah, Xie, Wanling, Nassar, Amin H, Dudani, Shaan, Martini, Dylan, Bakouny, Ziad, Steinharter, John A, Nuzzo, Pier Vitale, Flippot, Ronan, Martinez-Chanza, Nieves, Wei, Xiao, McGregor, Bradley A, Kaymakcalan, Marina D, Heng, Daniel Y C, Bilen, Mehmet A, Choueiri, Toni K, Harshman, Lauren C
Formato: Artigo
Lenguaje:Inglês
Publicado: BMJ Publishing Group 2020
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7057439/
https://ncbi.nlm.nih.gov/pubmed/32066646
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2019-000144
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares